Privia Health Group, Inc. (NASDAQ: PRVA) saw its stock surge 5.06% in pre-market trading on Thursday following the release of its second-quarter 2025 financial results. The healthcare company significantly outperformed earnings expectations and raised its full-year guidance, signaling strong growth and improved profitability.
Privia Health reported adjusted earnings per share of $0.24 for Q2, beating the analyst consensus estimate of $0.05 by an impressive 380%. This represents a 26.32% increase from the same period last year. While the company's quarterly revenue of $521.2 million missed the estimate of $800.1 million, it still showed a robust 23.4% year-over-year growth.
The company's strong performance was evident across key metrics. Implemented providers increased by 13.8% compared to Q2 2024, reaching 5,125. Value-based care attributed lives grew by 15.2% to 1,382,000, and practice collections surged 18.5% to $862.9 million. Notably, Privia Health raised its full-year 2025 guidance to above the high end of the previous range for practice collections, GAAP revenue, platform contribution, and adjusted EBITDA, reflecting management's confidence in continued growth and operational efficiency.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.